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Introduction {#sec005}
============

In 2013, the World Health Organization reported that at least 200 million individuals worldwide were diagnosed with asthma. The allergens were classified into two categories: indoor agents (such as pet dander, dust mites, tobacco smoke, and so forth) and outdoor agents (e.g., pollen, environmental pollutants, cold temperature, and so forth) \[[@pone.0224517.ref001]\]. Asthma is a type I allergy, and anaphylaxis. It is hard to completely eradicate and its symptoms are very diverse, ranging from cough to apnea. Patients with severe allergy may die from pulmonary obstruction and lack of gas exchange due to hypersecretion of mucus, overgrowth of pulmonary subepithelial cells, enlarged basement membrane, and accumulation of inflammatory cells near bronchioles and vessels \[[@pone.0224517.ref002],[@pone.0224517.ref003]\].

Among several theories of asthma occurrence, the imbalance between Th1 and Th2 cells plays a significant role in increasing the risk \[[@pone.0224517.ref002]\]. Cytokines such as interferon gamma (IFN-γ) that induce the release of Th1 cells are associated with the severity of asthma \[[@pone.0224517.ref004]\]. Interleukin 12 (IL-12) is an important cytokine that mediates Th1 cell differentiation and decreases Th2 cell proliferation \[[@pone.0224517.ref005]--[@pone.0224517.ref007]\]. Th2 cells release specific cytokines such as IL-4, IL-5, IL-13, and tumor necrosis factor-alpha (TNF-α) while IL-6 and IL-1β are Th17-related cytokines \[[@pone.0224517.ref008]\]. IL-4 is induced by GATA-3, a transcription factor with several bioactive functions, including stimulation of Th2-related cytokine expression \[[@pone.0224517.ref009]\], regulation of IgE levels \[[@pone.0224517.ref010]\], and so on. The level of IL-6 in asthma patients is substantially higher than in normal persons \[[@pone.0224517.ref011]\]. As one of the important factors that regulate asthma severity, IL-6 induces IL-4 up-regulation and stimulates Th17 cell differentiation \[[@pone.0224517.ref012]\]. IL-13 is linked to morphological changes in respiratory organs and B cell activation \[[@pone.0224517.ref013]--[@pone.0224517.ref016]\]. TNF-α is synthesized by macrophages \[[@pone.0224517.ref017]\]. It recruits neutrophils and eosinophils \[[@pone.0224517.ref018]\], stimulates T cell activation \[[@pone.0224517.ref019]\], and finally establishes airway hyperresponsiveness \[[@pone.0224517.ref020]\].

Inhaled corticosteroids are usually used to inhibit clinical asthma symptoms such as cough, respiratory depression, etc \[[@pone.0224517.ref021]\]. Asthma occurrence is higher in early childhood and elderly population than in the young and grown-up groups \[[@pone.0224517.ref001]\]. Inhaled corticosteroids are associated with serious adverse effects such as growth inhibition \[[@pone.0224517.ref022]\], cataracts, glaucoma, hypertension, hyperlipidemia, peptic ulcers, myopathy, and immunological suppression \[[@pone.0224517.ref023]\]. Therefore, efforts to discover new anti-asthmatic agents are ongoing and trials to investigate the mode of action on suppression or inhibition against asthma occurrence among the traditional medicines-related pulmonary diseases have increased.

Several hundred years ago in Korea, a medical encyclopedia known as *Donguibogam* was composed \[[@pone.0224517.ref024]\]. *Donguibogam* introduced *macmoondongtang*, a traditional prescription for the treatment of respiratory illness. *Macmoondongtang* is composed of plants such as *Glycyrrhizae radix*, *Oryza sativa*, *Zizyphus jujube* Inermis, *Ophiopogon japonicas*, *Pinellia ternate*, and *Panax ginseng*. Although *macmoondongtang* has been used to treat pulmonary disease recently, its mode of action has yet to be reported. Therefore, the objective of this study was to analyze the possible anti-asthmatic effect of *macmoondongtang* and the underlying mechanism of action.

Materials and methods {#sec006}
=====================

Preparation of *macmoondongtang* {#sec007}
--------------------------------

*Macmoondongtang* (Batch No. 14010, hot water extract-powder form) was manufactured by Hankuk Inspharm, Ltd. (Jeonnam, Korea) based on the prescription indicated in *Donguibogam* \[[@pone.0224517.ref024]\] and used in the present study. *Macmoondongtang* is generally available as an over-the-counter (OTC) drug. It contains *G*. *radix*, *O*. *sativa*, *Z*. *jujube* Inermis, *O*. *japonicas*, *P*. *ternate*, and *P*. *ginseng*. The dosage used in this study was calculated based the drug composition. The human equivalent dose (HED) for mice is 12.3 and the safety factor is 10×\[[@pone.0224517.ref025]\]. In this study, we applied 1/100 and 1/10 dosages for mouse based on therapeutic human dosage.

Identification of anti-asthmatic compounds in *macmoondongtang* {#sec008}
---------------------------------------------------------------

To analyze the levels of anti-asthmatic compounds in *macmoondongtang*, appropriate amounts of glycyrrhizin and liquiritin were accurately weighed and dissolved in methanol in 100 mL volumetric flasks to obtain stock solutions of 100 μg/mL. Solutions were subsequently serially diluted two-fold to 3.125 μg/mL. A sample measuring 0.5 g was dissolved in 10 mL methanol and sonicated to expedite the dissolution of particles. Subsequently, 1 mL was transferred to a volumetric flask and diluted with 9 mL of mobile phase A. The final concentration of *macmoondongtang* was 50 mg/mL. HPLC analysis was performed using an Alliance 2695 HPLC system (Waters, Milford, MA, USA) equipped with a photodiode array detector. A reverse phase column (C18, 5 μm, 150 mm × 5 mm) was used with a mobile phase consisting of a mixture of solvent A (acetonitrile) and B (0.2% acetic acid). The mobile phase conditions for glycyrrhizin were as follows: 0--35 min, gradient elution from 15/85 to 35/65 v/v; 35--50 min, gradient elution from 35/65 to 100/0 v/v; and 50--55 min, from 100/0 to 15/85 v/v. The mobile phase conditions for liquiritin were as follows: 0--8 min, gradient elution from 10/90 to 20/80 v/v; 8--20 min, gradient elution from 20/80 to 25/75 v/v; 20--21 min, from 25/75 to 100/ v/v; and 21--30 min, from 100/0 to 10/90 v/v. The flow rate was 1.0 mL/min, and the injection volume was 10 μL.

Animal experiments {#sec009}
------------------

The animal study investigating the anti-asthmatic effect of *macmoondongtang* was followed by a confirmative study. For each study, 35 female BALB/c mice were purchased from Samtako Korea (Osan, Korea) and divided into five groups according to the treatment: vehicle control (tap water), ovalbumin (OVA)-treated group, OVA-treated group exposed to 1 mg/kg dexamethasone, OVA-treated group exposed to 150 and 1500 mg/kg *macmoondongtang*. The following doses were injected intraperitoneally into all animals except the control group: 20 μg OVA (Sigma-Aldrich, St. Louis, MO, USA) and 1 mg aluminum hydroxide hydrate (Sigma-Aldrich) in 500 μL saline. A week after injection of the second booster dose, all animals except the control group were exposed to OVA including a first inhalation dose for 5 days after OVA challenge. The animals were treated orally with tap water, dexamethasone, and 2 doses of *macmoondongtang*.

Ethics statement {#sec010}
----------------

This animal study was conducted following approval by the Institutional Animal Care and Use Committee of Dongshin University (Animal Study Approval No. 2014-08-02).

Bronchoalveolar fluid (BALF) and serum analysis {#sec011}
-----------------------------------------------

Bronchioalveolar fluid (BALF) was collected from all mice under anesthesia on a day after the final treatment. BALF was collected using 0.4 mL cold phosphate-buffered saline (PBS). The white blood cell (WBC) count and differential blood count were performed with the collected fluid using Hemavet Multispecies Hematology System (Drew Scientific Inc, Waterbury, CT, USA). Inflammatory cells in BALF were stained with Diff-Quick method \[[@pone.0224517.ref026]\].

Serum IgE levels were evaluated using ELISA.

Histopathological analysis {#sec012}
--------------------------

In order to observe the morphological changes, lungs were fixed in formaldehyde, dehydrated in ethanol, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. In order to compare the levels of released glycoprotein, periodic acid Schiff (PAS) stain was used. Subsequently, the images were acquired with Axioscope A1 (Carl Zeiss, Gottingen, Germany).

Reverse transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunoassay (ELISA) {#sec013}
----------------------------------------------------------------------------------------------

In order to evaluate changes in the cDNA levels of IFN-γ, IL-12p40, IL-4, IL-5, IL-13, TNF-α, and IL-6, which are related to asthma induction, RT-PCR analysis was conducted as reported in our previous study protocol (Lee et al., 2017). Total RNA was extracted from the lung using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Total RNA (100 ng) was used as a template for the reaction. Primers were synthesized for RT-PCR as shown in [Table 1](#pone.0224517.t001){ref-type="table"}. The RT-PCR cycles consisted of denaturation at 95°C for 5 s and annealing/extension at 65°C for 30 s for 40 cycles using with QTOWER2.2. (Analytik Jena AG, Thuringia, Germany). The serum levels of IgE were measured using a specific mouse IgE enzyme-linked immunosorbent assay kit (BD bioscience, 555248, San Jose, CA, USA) according to the manufacturer\'s protocols.
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###### Primer sequences for RT-PCR.

![](pone.0224517.t001){#pone.0224517.t001g}

  Genes     Primer sequences                   
  --------- ---------------------------------- ---------------------------------
  IFN-γ     Forward                            `5′-GGCCATCAGCAACAACATAAG-3′`
  Reverse   `5′-GTTGACCTCAAACTTGGCAATAC-3′`    
  IL-12p    Forward                            `5′-GGACCAAAGGGACTATGAGAAG-3′`
  Reverse   `5′-CTTCCAACGCCAGTTCAATG-3′`       
  IL-4      Forward                            `5′-ACAGGAGAAGGGACGCCAT-3′`
  Reverse   `5′-GAAGCCCTACAGACGAGCTCA-3′`      
  IL-5      Forward                            `5′-TGCATCAGGGTCTCAAGTATTC-3′`
  Reverse   `5′-GGATGCTAAGGTTGGGTATGT-3′`      
  IL-13     Forward                            `5′-CAGCCCTCAGCCATGAAATA-3′`
  Reverse   `5′-CTTGAGTGTGTAACAGGCCATTCT-3′`   
  IL-6      Forward                            `5′-GATAAGCTGGAGTCACAGAAGG-3′`
  Reverse   `5′-TTGCCGAGTAGATCTCAAAGTG-3′`     
  TNF-α     Forward                            `5′-CTGAGTTCTGCAAAGGGAGAG-3′`
  Reverse   `5′-CCTCAGGGAAGAATCTGGAAAG-3′`     
  GAPDH     Forward                            `5′-GTGGAGTCATACTGAACATGTAG-3′`
  Reverse   `5′-AATGGTGAAGGTCGGTGTG-3′`        

Immunofluorescent analysis {#sec014}
--------------------------

In order to localize the expression of Th1 cell transcription factor, T-bet, and Th2 cell transcription factor, GATA-3 immunofluorescent analysis was conducted. Only four groups were evaluated: control, OVA, dexamethasone plus OVA treatment, and 1500 mg/kg *macmoondongtang* plus OVA treatment. Prior to the antibody binding step, the same materials were used for immunohistochemical analysis; however, rabbit anti-mouse T-bet (Biorbyt, orb7075, Cambridge, UK) or goat anti-mouse GATA-3 (OriGene, TA305795, Rockville, MD, USA) were used as primary antibodies for 1 h at room temperature. The slides were incubated for 2 h with FITC-conjugated anti-rabbit IgG (Jackson Immunoresearch, 315-095-003, West Grove, PA, USA) or Alexa Fluor^®^ 555-conjugated anti-goat IgG (ThermoFisher Scientific, A-21127, Waltham, MA, USA). The cells were counterstained with DAPI (ThermoFisher Scientific, 62249, Waltham, MA, USA). The images were obtained using a K1-Fluo confocal microscope (Nanoscope System, Daejeon, Korea).

Immunohistochemical analysis {#sec015}
----------------------------

In order to analyze the changes in the levels of asthma-related protein, immunohistochemistry was performed using antibodies such as IFN-γ (Santa Cruz, sc-74104), IL-12p40 (Santa Cruz, sc-57258), IL-4 (Santa Cruz, sc-73318), IL-5 (Santa Cruz, sc-7887), IL-13 (Santa Cruz, sc-1776), IL-6 (Santa Cruz, sc-1265), and TNF-α (BioVision, 3053R-100, Milpitas, CA, USA) and the dilution rate ranged from 1:100 to 1:200. The slides were incubated with a biotinylated pan-specific secondary antibody for 10 min and reacted with the streptavidin-peroxidase complex for 5 min (Vector Laboratories Universal Quick Kit, Burlingame, Canada). Signals were detected using 3,3-diaminobenzidine tetrahydrochloride substrate chromogen solution. Cells were counterstained with Mayer's hematoxylin. Subsequently, the cells were imaged using Axioscope A1 (Carl Zeiss).

Statistical analysis {#sec016}
--------------------

Results are expressed as the mean ± standard deviation (SD). Group differences were evaluated via one-way analysis of variance followed by Dunnett's multiple comparison tests. Significance was considered at *p* \< 0.01 or *p* \< 0.05.

Results {#sec017}
=======

*Macmoondongtang* contains two anti-asthmatic markers: Glycyrrhizin and liquiritin {#sec018}
----------------------------------------------------------------------------------

HPLC analyses were performed to identify the anti-asthmatic compounds and immune modulators in *macmoondongtang*. Typical HPLC chromatograms and their retention times are shown in [Fig 1](#pone.0224517.g001){ref-type="fig"}. Glycyrrhizin (0.38 ± 0.002%), and liquiritin (0.02 ± 0.0002%) were identified using HPLC analysis.

![HPLC results of *macmoondongtang*.\
(A) standard- liquiritin and paeoniflorin; (B) *macmoondongtang*, 50 mg/mL, (C) standard-glycyrrhizin; (D) macmoondongtang, 25 mg/mL.](pone.0224517.g001){#pone.0224517.g001}

*Macmoondongtang* suppresses ovalbumin-induced hyperproliferation of inflammatory cells and immune cells {#sec019}
--------------------------------------------------------------------------------------------------------

OVA treatment significantly boosts the levels of inflammatory and immune cells such as white blood cells, eosinophils, and neutrophils in the lung \[[@pone.0224517.ref027]\]. *Macmoondongtang* induced a dose-dependent suppression of inflammatory cells, which were increased by OVA treatment ([Fig 2A](#pone.0224517.g002){ref-type="fig"} and [S1 File](#pone.0224517.s001){ref-type="supplementary-material"}). We used dexamethasone as a positive control during the treatment with macmoondongtang as it is generally used to manage acute asthma exacerbation \[[@pone.0224517.ref028]\]. As shown in [Fig 2B--2D](#pone.0224517.g002){ref-type="fig"}, the WBC, eosinophil, and neutrophil counts in the dexamethasone treatment group were significantly decreased compared with the OVA-induced asthma group. However, *macmoondongtang* treatment suppressed their proliferation dose-dependently. Especially, the number of neutrophils in the group treated with1500 mg/kg *macmoondongtang* was significantly decreased ([Fig 2D](#pone.0224517.g002){ref-type="fig"}) similar to the group treated with dexamethasone.

![*Macmoondongtang* treatment suppressed infiltration of both inflammatory cells and immune cells such as white blood cells (WBCs), eosinophils, and neutrophils.\
(A) *Macmoondongtang* effectively decreased OVA-induced proliferation of inflammatory cells. (B) *Macmoondongtang* dose-dependently down-regulated the population of WBCs. (C) *Macmoondongtang* effectively suppressed the number of eosinophils. (D) *Macmoondongtang* significantly and dose-dependently decreased neutrophil proliferation. **a**, vehicle control; **b**, asthma induction; **c**, dexamethasone; **d**, 150 mg/kg/day *macmoondongtang*; **e**, 1500 mg/kg/day *macmoondongtang*. Each bar represents the mean ± SD (n = 8). \**p* \< 0.05 vs. control; \*\**p* \< 0.001 vs. control; ^\$^*p* \< 0.05 vs. asthma induction; ^\$\$^*p* \< 0.01 vs. asthma induction; ^\#^*p* \< 0.05 vs. dexamethasone. Scale Bar = 100 μm. Magnification, ×400.](pone.0224517.g002){#pone.0224517.g002}

*Macmoondongtang* induces dose-dependent suppression of IgE {#sec020}
-----------------------------------------------------------

IgE levels usually surge in allergy and increase significantly in asthma \[[@pone.0224517.ref029]\]. Serum IgE levels in OVA-induced asthma group (60.17 ± 8.135 ng/mL) were significantly increased compared to the levels (13.98 ± 3.877 ng/mL) in the control ([Fig 3](#pone.0224517.g003){ref-type="fig"} and [S1 File](#pone.0224517.s001){ref-type="supplementary-material"}). Although the serum IgE level in dexamethasone-treated group was higher than in the control, the increased level of IgE induced by OVA treatment was down-regulated to 34.00 ± 8.351 ng/mL (57% compared with OVA treatment) after dexamethasone treatment. *Macmoondongtang* controlled the IgE level in a dose-dependent manner: 54.91 ± 10.141 ng/mL in the group treated with 150 mg/kg and 44.35 ± 9.618 ng/mL in the group exposed to 1500 mg/kg. There was no significant difference in serum IgE levels between groups treated with dexamethasone and 1500 mg/kg of *macmoondongtang*, which suggested that 1500 mg/kg *macmoondongtang* was adequate to treat asthma patients.

![*Macmoondongtang* treatment effectively suppressed serum IgE level in a dose-dependent manner.\
Serum IgE level in the group treated with 1500 mg/kg *macmoondongtang* was compared with that of dexamethasone-treated group. Each bar represents the mean ± SD (n = 16). \*\**p* \< 0.001 vs. control; ^\$^*p* \< 0.05 vs. asthma induction; ^\$ \$^*p* \< 0.01 vs. asthma induction; ^\#^*p* \< 0.05 vs. dexamethasone.](pone.0224517.g003){#pone.0224517.g003}

*Macmoondongtang* dose-dependently inhibits typical morphological changes in OVA-induced asthma model {#sec021}
-----------------------------------------------------------------------------------------------------

To evaluate morphological changes in the lung, H&E staining was performed ([Fig 4A](#pone.0224517.g004){ref-type="fig"}). The OVA-treated group showed typical morphological changes such as inflammatory cell infiltration (purple color) near bronchioles and vessels, pulmonary hyperplasia (thickening inner bronchiole), and mucous hypersecretion (purple color) in the bronchiole ([Fig 4Bb](#pone.0224517.g004){ref-type="fig"}) compared with the control ([Fig 4Aa](#pone.0224517.g004){ref-type="fig"}). Dexamethasone controlled OVA-induced morphological changes in the lung by decreasing inflammatory cell infiltration near bronchioles and vessels and inhibiting basal membrane thickening of inner bronchioles and mucous secretion ([Fig 4Ac](#pone.0224517.g004){ref-type="fig"}). It Fewer differences in lung morphology were detected between groups treated with OVA ([Fig 4Ab](#pone.0224517.g004){ref-type="fig"}) and 150 mg/kg *macmoondongtang* ([Fig 4Ad](#pone.0224517.g004){ref-type="fig"}). However, OVA-induced asthmatic changes in the lung were reversed by treatment with 1500 mg/kg *macmoondongtang* ([Fig 4Ae](#pone.0224517.g004){ref-type="fig"}), although the recovery was less than that induced by dexamethasone.

![*Macmoondongtang* dose-dependently inhibited typical morphological changes in the lungs of mice with OVA-induced asthma.\
(A) *Macmoondongtang* controlled base membrane thickening caused by epithelial cell hyperplasia, inflammatory infiltration near bronchiole and vessel, mucous hypersecretion, and other changes based on H&E staining. (B) *Macmoondongtang* dose-dependently suppressed mucous secretion based on PAS staining. **a**, vehicle control; **b**, asthma induction; **c**, dexamethasone; **d**,150 mg/kg/day *macmoondongtang*; **e**, 1500 mg/kg/day *macmoondongtang*. Br, bronchioalveolar region; V, vessel. Scale Bar = 50 μm. Magnification, ×200.](pone.0224517.g004){#pone.0224517.g004}

In the case of asthma patients, breathing difficulty is usually observed due to factors such as pulmonary base membrane thickening due to epithelial cell hyperplasia and mucous hypersecretion \[[@pone.0224517.ref016]\]. Mucous hypersecretion in the bronchiole can directly inhibit breathing, and therefore, is a very important parameter for the evaluation of asthma severity. To determine the effect of *macmoondongtang* on mucous secretion, PAS staining was conducted ([Fig 4B](#pone.0224517.g004){ref-type="fig"}). In the control, no mucus was detected in the bronchiole ([Fig 4Ba](#pone.0224517.g004){ref-type="fig"}). However, in the OVA-treated group ([Fig 4Bb](#pone.0224517.g004){ref-type="fig"}) and the group treated with 150 mg/kg macmoondongtang ([Fig 4Bd](#pone.0224517.g004){ref-type="fig"}), the bronchiole was almost obstructed by mucus (purple color). There was little difference in mucus levels between the groups treated with dexamethasone ([Fig 4Bc](#pone.0224517.g004){ref-type="fig"}) and 1500 mg/kg *macmoondongtang* ([Fig 4Be](#pone.0224517.g004){ref-type="fig"}). These results indicate that *macmoondongtang* dose-dependently suppresses mucous secretion.

*Macmoondongtang* effectively induces inactivation of both Th1 and Th2 cell transcription factors {#sec022}
-------------------------------------------------------------------------------------------------

Asthma is caused by the imbalance of Th1 and Th2 cells \[[@pone.0224517.ref002]\]. T-bet is a Th1 cell transcription factor \[[@pone.0224517.ref030], [@pone.0224517.ref031]\] while GATA-3 is a Th2 cell transcription factor \[[@pone.0224517.ref009]\]. GATA-3 immunofluorescent assay was conducted to evaluate the changes in the activation levels of Th1 cell transcription factor, T-bet, and Th2 cell transcription factor ([Fig 5](#pone.0224517.g005){ref-type="fig"}). The activated transcription factors are translocated from the cytoplasm to nuclei. The distribution of T-bet (green color, [Fig 5B](#pone.0224517.g005){ref-type="fig"}) was similar to that of GATA-3 (red color, [Fig 5C](#pone.0224517.g005){ref-type="fig"}). OVA treatment activated both Th1 and Th2 transcription factors in the nuclei ([Fig 5Db](#pone.0224517.g005){ref-type="fig"}). However, in the other groups, both T-bet and GATA-3 remained localized to the cytoplasm ([Fig 5Da, 5Dc & 5Dd](#pone.0224517.g005){ref-type="fig"}). These results indicate that *macmoondongtang* inhibited the activation of both Th1 and Th2 cell transcription factors.

![*Macmoondongtang* effectively induced the inactivation of both Th1 and Th2 cell transcription factors.\
(A) Nuclei are shown in blue color by DAPI staining. (B) Images displaying results of T-bet staining by FITC. (C) GATA-3 staining by AlexaFluor® 555. (D) Merged images of nuclei stained with DAPI, T-bet stained with FITC, and GATA-3 stained with Alexa Fluor® 555. Treatment with dexamethasone and *macmoondongtang* completely abrogated the activation of both Th1 cell transcription factor T-bet and Th2 cell transcription factor GATA-3. **a**, vehicle control; **b**, asthma induction; **c**, dexamethasone; **d**,1500 mg/kg/day macmoondongtang. Scale Bar = 100 μm. Magnification, ×1000.](pone.0224517.g005){#pone.0224517.g005}

*Macmoondongtang* significantly suppresses both gene and protein expression of IFN-γ and IL-12 {#sec023}
----------------------------------------------------------------------------------------------

To analyze the levels of Th1-related cytokines such as IFN-γ and IL-12, we conducted RT-PCR ([Fig 6A](#pone.0224517.g006){ref-type="fig"} and [S1 File](#pone.0224517.s001){ref-type="supplementary-material"}) and IHC staining ([Fig 6B and 6C](#pone.0224517.g006){ref-type="fig"}). As shown in [Fig 6A](#pone.0224517.g006){ref-type="fig"}, *macmoondongtang* effectively and dose-dependently inhibited *IFN-γ* gene expression, which was dramatically up-regulated by OVA treatment. *IFN-γ* gene expression in the group treated with 1500 mg/kg *macmoondongtang* was similar to that of the group treated with dexamethasone. Similar to changes in the expression of *IFN-γ* gene, the protein expression induced by OVA treatment was also suppressed by *macmoondongtang* ([Fig 6B](#pone.0224517.g006){ref-type="fig"}). Changes in gene and protein expression of IL12p40 were similar to those of IFN-γ ([Fig 6A and 6C](#pone.0224517.g006){ref-type="fig"}).

![Treatment with *macmoondongtang* significantly down-regulated gene and protein expression of IFN-γand IL-12p40.\
*Macmoondongtang* dose-dependently controlled both *IFN-γ* gene expression quantified by RT-PCR (A) and IFN-γ protein levels assessed by IHC (B). *Macmoondongtang* also regulated *IL-12* gene expression and up-regulated gene and protein expression of IL-12p40 in the lung (C). **a**, vehicle control; **b**, asthma induction; **c**, dexamethasone; **d**, 150 mg/kg/day *macmoondongtang*; **e**, 1500 mg/kg/day *macmoondongtang*. Each bar represents the mean ± SD (n = 8). \**p* \< 0.05 vs. control; \*\**p* \< 0.001 vs. control; ^\$^*p* \< 0.05 vs. asthma induction; ^\#^*p* \< 0.05 vs. dexamethasone. Scale Bar = 50 μm. Magnification, ×200.](pone.0224517.g006){#pone.0224517.g006}

*Macmoondongtang* controls the expression of IL-4 and IL-5, but not IL-13, in a dose-dependent manner {#sec024}
-----------------------------------------------------------------------------------------------------

OVA treatment significantly suppressed the expression of *IL-5* and *IL-13* genes, but not that of *IL-4* gene, although it varied depending on treatment materials such as sterilized tap water (control), dexamethasone, and *macmoondongtang* ([Fig 7A](#pone.0224517.g007){ref-type="fig"} and [S1 File](#pone.0224517.s001){ref-type="supplementary-material"}). However, *macmoondongtang* significantly down-regulated the expression of *IL-5* gene alone. The gene expression of Th2-related cytokines differed from their protein levels in the respiratory system ([Fig 7B--7D](#pone.0224517.g007){ref-type="fig"}). Although the *IL-5* gene expression was statistically significant after *macmoondongtang* treatment, the protein expression of all Th2-related cytokines in the present study such as IL-4, IL-5, and IL-13 was dose-dependently suppressed by *macmoondongtang* treatment. The levels of IL-4 ([Fig 7Be](#pone.0224517.g007){ref-type="fig"}), IL-5 ([Fig 7Ce](#pone.0224517.g007){ref-type="fig"}) and IL-13 proteins ([Fig 7De](#pone.0224517.g007){ref-type="fig"}) in the group treated with 1500 mg/kg *macmoondongtang* were significantly decreased compared with those of the dexamethasone-treated group ([Fig 7Cc & 7Dc](#pone.0224517.g007){ref-type="fig"}).

![*Macmoondongtang* dose-dependently suppressed Th2-related cytokines such as IL-4, IL-5, and IL-13.\
*Macmoondongtang* significantly and effectively inhibited the gene expression of *IL-5* (A) and IL-5 protein level (C). The treatment dose-dependently controlled the IL-4 protein expression (B). Similar changes at the gene (A) and protein levels of IL-13 (D) were observed as those for IL-5. **a**, vehicle control; **b**, asthma induction; **c**, dexamethasone; **d**,150 mg/kg/day *macmoondongtang*; **e**, 1500 mg/kg/day *macmoondongtang*. Each bar represents the mean ± SD (n = 8). \**p* \< 0.05 vs. control; \*\**p* \< 0.001 vs. control; ^\$^*p* \< 0.05 vs. asthma induction; ^\#^*p* \< 0.05 vs. dexamethasone. Scale Bar = 50 μm. Magnification, ×200.](pone.0224517.g007){#pone.0224517.g007}

*Macmoondongtang* modulates the expression of TNF-α, but not IL-6 {#sec025}
-----------------------------------------------------------------

OVA treatment increased the levels of only *TNF-α* gene ([Fig 8A](#pone.0224517.g008){ref-type="fig"} and [S1 File](#pone.0224517.s001){ref-type="supplementary-material"}). Dexamethasone significantly decreased the expression of *TNF-α* gene while *macmoondongtang* dose-dependently suppressed its level. Especially, treatment with 1500 mg/kg *macmoondongtang* suppressed the expression of *TNF-α* gene similar to that of dexamethasone-treated group. *Macmoondongtang* down-regulated TNF-α expression in a dose-dependent manner ([Fig 8B](#pone.0224517.g008){ref-type="fig"}). However, it did not suppress the level of IL-6, which was increased by OVA treatment ([Fig 8Cc, 8Cd & 8Ce](#pone.0224517.g008){ref-type="fig"}). The TNF-α level was decreased by treatment with 1500 mg/kg *macmoondongtang* ([Fig 8Be](#pone.0224517.g008){ref-type="fig"}), similar to that of dexamethasone treatment ([Fig 8Bc](#pone.0224517.g008){ref-type="fig"}).

![*Macmoondongtang* treatment significantly inhibited *TNF-α* gene and protein expression, but not that of IL-6.\
*Macmoondongtang* dose-dependently suppressed the gene (A) and protein expression (B) of TNF-α but not that of IL-6 expression (C). **a**, vehicle control; **b**, asthma induction; **c**, dexamethasone; **d**,150 mg/kg/day *macmoondongtang*; **e**, 1500 mg/kg/day *macmoondongtang*. Each bar represents the mean ± SD (n = 8). \**p* \< 0.05 vs. control; ^\$^*p* \< 0.05 vs. asthma induction. Scale Bar = 50 μm. Magnification, ×200.](pone.0224517.g008){#pone.0224517.g008}

Discussion {#sec026}
==========

Environmental allergens inducing asthma are classified into two types: indoor allergens (for e.g., pet dander, dust mite, tobacco smoke, etc.) and outdoor allergens (for e.g., pollen, environmental pollutants, cold temperature, etc.) \[[@pone.0224517.ref032]\]. At first, antigen-presenting cells (APCs) recognize repeated invasion by allergens, leading to asthma. Studies have been performed to verify the relation between type 1 allergy and IgE, an important and representative biomarker \[[@pone.0224517.ref029], [@pone.0224517.ref033]\]. Accordingly, IgE increase is a very important factor that triggers asthma, suggesting the need to decrease IgE expression induced by OVA exposure. Immune response is critical to maintain the homeostasis of Th1 and Th2 cells in living organisms. The hypothesis of Th1/Th2 balance for immune system was introduced in the 1980s \[[@pone.0224517.ref034]\]. Asthma is one of the diseases triggered by Th1/Th2 imbalance and according to the theory \[[@pone.0224517.ref035]\], the balance between Th1 cells and Th2 cells is generally maintained. However, an up-regulation of Th2 cells including related cytokines may trigger asthma. IFN-γ and IL-12 are Th1 cytokines, whereas IL-4, IL-5, and IL-13 are Th2 cytokines, and IL-6 and TNF-α are Th17-related cytokines\[[@pone.0224517.ref010]\].

T-bet is a factor associated with Th1 cell transcription. T-bet and IFN-γ show a positive feed-back \[[@pone.0224517.ref030], [@pone.0224517.ref036]\]. IL-12p40 is one of the key factors regulating Th1-related cytokines in that it specifically stimulates IFN-γ production in asthma \[[@pone.0224517.ref005]\]. As shown in [Fig 6](#pone.0224517.g006){ref-type="fig"}, changes in IFN-γ gene and protein levels were very similar to those of IL-12p40 while *macmoondongtang* effectively inhibited their increases.

In asthma patients, the Th2-related cytokines such as IL-4, IL-5, and IL-13 are usually increased \[[@pone.0224517.ref037]--[@pone.0224517.ref039]\]. GATA-3 is a Th2 cell transcription factor. IL-4 increases its activation. Consequentially, the regulation of GATA-3 and IL-4 produces Th2-related cytokines \[[@pone.0224517.ref009]\]. *Macmoondongtang* not only significantly inactivated both Th1 and Th2 transcription factors ([Fig 5](#pone.0224517.g005){ref-type="fig"}), but also suppressed gene and protein levels of IFN-γ and IL-4 directly linked to each transcription factor (Figs [6A](#pone.0224517.g006){ref-type="fig"}, [6B](#pone.0224517.g006){ref-type="fig"}, [7A and 7B](#pone.0224517.g007){ref-type="fig"}).

Recognition of APCs by Th2 cells not only releases cytokines such as IL-4, IL-5, and IL-13 that stimulate IgE surge via B cell activation, but also increases the eosinophil population induced by IL-5 to initiate airway remodeling \[[@pone.0224517.ref033], [@pone.0224517.ref040]\]. In the lung, increased IL-13 expression is extensively associated with airway hyper-responsiveness such as inflammation, mucous hypersecretion, epithelial fibrosis, and airway obstruction \[[@pone.0224517.ref016]\]. *Macmoondongtang* controlled the levels of all Th2-related cytokines investigated such as IL-4, IL-5, and IL-13. It specifically suppressed the expression of IL-4 and IL-5 ([Fig 7A--7C](#pone.0224517.g007){ref-type="fig"}). These results explain the anti-asthmatic effect of *macmoondongtang* mediated via suppression of serum IgE level ([Fig 3](#pone.0224517.g003){ref-type="fig"}) to reverse the typical morphological changes associated with asthma such as epithelial hyperplasia, mucous hypersecretion, and airway obstruction ([Fig 4](#pone.0224517.g004){ref-type="fig"}).

Th17-related cytokines such as TNF-α, IL-6, and IL-1β are important in the control of asthma onset \[[@pone.0224517.ref041]\]. TNF-α is one of the chemo-attractants for neutrophils and eosinophils \[[@pone.0224517.ref018]\]. It induces death of eosinophils via oxidative stress in pulmonary epithelial cells \[[@pone.0224517.ref042]\]. Although eosinophil numbers are increases in many asthma patients, other patients show a surge in neutrophil levels \[[@pone.0224517.ref043]\]. In the present study, *macmoondongtang* effectively suppressed the proliferation of eosinophils and neutrophils in BALF and inhibited eosinophil infiltration near bronchioles and alveoli, and vessels via TNF-α modulation ([Fig 2](#pone.0224517.g002){ref-type="fig"}). The expression of IL-6 in asthma patients is significantly increased \[[@pone.0224517.ref044]\]. The IL-6 induced by allergens stimulates the release of IL-4 and IL-13 from Th2 cells \[[@pone.0224517.ref012]\]. IL-6 may be one of the key factors maintaining the balance of helper T cells to control Treg cells or Th17 cells \[[@pone.0224517.ref044]\].

Several reports suggest the anti-asthmatic effects of herbal extracts \[[@pone.0224517.ref045]--[@pone.0224517.ref047]\] or compounds derived from natural products \[[@pone.0224517.ref048]\]. However, the bioactivity of may be associated with specific compounds derived from herbs or mushrooms. The anti-asthmatic effect was attributed to bioactive ingredient(s) in the natural product. *Macmoondongtang* used in this study was obtained as an extract from several herbs such as *Glycyrrhizae radix*, *Oryza sativa*, *Zizyphus jujube* Inermis, *Ophiopogon japonicas*, *Pinellia ternate*, and *Panax ginseng*. A review of literature suggests that *macmoondongtang* contains anti-asthmatic markers such as glycyrrhizin and anti-inflammatory markers such as liquiritin. To determine the bioactive compounds in macmoondongtang, HPLC analysis was conducted. Results showed that glycyrrhizin (0.38%) and liquiritin (0.02%) were present in the *macmoondongtang* extract. Glycyrrhizin is one of the major compounds in *Glycyrrhiza uralensis* and *Glycyrrhiza glabra*. Ram *et al*. (2006) reported that glycyrrhizin exhibits an immunomodulatory effect in a mouse model of asthma \[[@pone.0224517.ref049]\]. Oral administration of glycyrrhizin (2.5 to 20 mg/kg) to OVA-induced mice resulted in a suppression of IL-4, IL-5, IFN-γ, and IgE levels. In the present study, we identified liquiritin content in *macmoondongtang* extract. Liquiritin modulates inflammation via inhibition of pro-inflammatory mediators such as inducible nitric oxide synthase, cyclooxygenase (COX)-2, TNF-α, IL-1β, and IL-6 \[[@pone.0224517.ref050], [@pone.0224517.ref051]\]. Thus, liquiritin occurring in *macmoondongtang* may alleviate the inflammatory symptoms caused by asthma. Although *G*. *auralensis* contains glycyrrhizin and *G*. *glabra* has liquiritin, each herb exhibits a typical anti-asthmatic effect.

Ram *et al*. (2006) have reported that an oral dose starting with 5 mg/kg of liquiritin was effective in mice \[[@pone.0224517.ref049]\]. In the present study, we found that *macmoondongtang* resulted in an anti-asthmatic effect at a dose of 1500 mg/kg in our animal model. The dose of 1500 mg/kg corresponds to 5.7 mg/kg of glycyrrhizin. Thus, the curative dose in the present study was consistent with that of the previous report, suggesting that glycyrrhizin contained in *macmoondongtang* is a possible therapeutic candidate for the management of asthma. Furthermore, we evaluated a daily oral dose of 7.3 g *macmoondongtang* for treatment of asthma. The therapeutically effective oral dose of *macmoondongtang* in mouse was 1500 mg/kg/day. The conversion factor between human and mouse is 12.3 \[[@pone.0224517.ref021]\]. Therefore, if the effective dose of *macmoondongtang* in mice is 1500 mg/kg/day, the human equivalent dose is 7300 mg/60kg/day. The recommended daily intake of *macmoondongtang* for human is 9 g. Thus, the optimal dose for asthma treatment is less than its daily intake and then we could confirm that oral intake of macmoondongtang at a dose of 7.3 g might prevent the occurrence of asthma.

From the results we concluded that Macmoondongtang treatment alleviates asthma symptoms and modulate the Th1-/Th2- related cytokines. Glycyrrhizin and liquiritin could be the major the active therapeutic components.

Supporting information {#sec027}
======================

###### This file is raw data for making graphs in [Fig 2](#pone.0224517.g002){ref-type="fig"}, [Fig 3](#pone.0224517.g003){ref-type="fig"}, [Fig 6](#pone.0224517.g006){ref-type="fig"}, [Fig 7](#pone.0224517.g007){ref-type="fig"} and [Fig 8](#pone.0224517.g008){ref-type="fig"}.
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Macmoondongtang modulates asthma-related changes via modulation of TNF-a and T-bet & IFN-r in an asthma murine model
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Dear Professor Park,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Sep 07 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Michal A Olszewski, DVM, PhD

Academic Editor
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Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (<http://learn.aje.com/plos/>) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website ([www.editage.com](http://www.editage.com)) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.
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The name of the colleague or the details of the professional service that edited your manuscriptA copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a \*supporting information\* file)A clean copy of the edited manuscript (uploaded as the new \*manuscript\* file)

Additional Editor Comments:

While parts of the manuscript were found to be interesting, there were several serious concerns that need to be addressed before the manuscript could meat the criteria for publication in PLOS One.

Please ensure that all the reviewers\' comments are addressed and the conclusions always match the presented data. Please make sure that the N values for individual groups/time points are specified and they type of statistical analysis is always clearly disclosed.

Finally, in addition to the reviewers\' comments, the histology images are low resolution and often out of focus, which makes the evaluation of histology panels difficult.

Please retake the pictures as needed and provide the high-resolution files to ensure that the histology data are clearly presented. Whenever, possible the multi-panel figures could be divided into multiple figures so that the individual histology images could be magnified for improved visibility.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Comment \#1

The manuscript entitled with "Macmoondongtang modulates asthma-related changes via modulation of TNF-a and T-bet & IFN-r in an asthma murine model" brought some interesting findings. However, it is not convincible for its description and conclusion with several reasons as follows:

1\) Macmoondongtang has been used as a traditional prescription for pulmonary disease in Korea. However, there is no report about the mechanism involved in its effect. In the present study, the authors described how Macmoondongtang as a repiratory medicine has effect on Ashma in a murine model. Since Macmoondongtang is a traditional prescription for pulmonary disease, surprisingly, there is no any information on how Macmoondongtang has been clinically used in Ashma treatment at all. So, it is really weird for me to choose Ashma instead of the other disease models for study on Macmoondongtang.

2\) According to the results, it looks like that Macmoondongtang play role in modulation of expression of Th1, Th2 and Th17-related cytokines. Why did the manuscript choose a tittle as modulation of TNF-a and T-bet & IFN-r? It doesn\'t make any sense to me.

3\) The results showed that Macmoondongtang contained glycyrrhizin and liquiritin. Theoretically glycyrrhizin and liquiritin could have some role in modulation of the cytokine expression. But how did you exclude effects of some unknown components in Macmoondongtang.

Comment \#2

Has the statistical analysis been performed appropriately and rigorously? No Although the manuscript showed thirty-fine mice were divided into five groups, it was not clear of how many mice had being used in each figure. So, it is very confused about how they calculated the data without showing "n" in each figure.

Comment \#3

Is the manuscript presented in an intelligible fashion and written in standard English? No

There are a lot of places to be rewrote in a standard English in this manuscript, for example, "It is important to decrease IgE expression increased by ovalbumin treatment", "T-bet is a factor for Th1 cell transcription...., to the end of this paraph", and so on.

Some minor comments:

1\) For material and methods, there were a lot of description to be improved, for example, which samples were used for RNA extraction? how the samples were prepared for IFA? and so on.

2\) What's magnitude for those microscopic figures? And the quality of those microscopic figures should be also improved.

Reviewer \#2: In this study, Lee et al. reported that macmoondongtang, a traditional prescription for treating respiratory disease, could modulate host immune responses during OVA-induced asthma in a mice model. They reported that macmoondongtang treatment could reduce serum IgE level, mucus hypersecretion, inflammatory cell infiltration in the lungs. They also reported that macmoondongtang treatment leads to reduced expression of Th1/Th2 transcriptional factors as well as related cytokines such as IFN-g, IL-12, IL-4 and IL-5, IL-13 on mRNA level or protein level. The data is interesting; however, the manuscript has severe limitations that the authors need to deal with before publications.

1\. The written Englished should be revised significantly. There are many grammar mistakes in the manuscript.

2\. The conclusions are overstated and need revision. For example,

a\. it is not convincing that glycyrrhizin and liquiritin were the effective ingredients of macmoondongtang.

b\. There is no data supporting the title: "Macmoondongtang modulates asthma-related changes via modulation of TNF-a and Tbet & IFN-g in an asthma murine model". They showed correlation, nut not causality.

3\. The reviewer also concerned about the quality of some data. For example, fig 5, it is hard to tell the localization of the transcriptional factors (Tbet and GATA3) at the current magnification. Fig 6, 7, 8, it would be nice to quantify the IHC signals.

4\. Methods are missing: RNA isolation, cDNA synthesis, qPCR methods, Elisa for IgE,

5\. Fig 1, please also include the control HPLC data for glycyrrhizin and liquiritin.

6\. For statistical analysis, how many times have these experiments been repeated? It says mean ± SEM in the figure legends but mean ± SD in the Materias and Methods, which one is correct?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1

Comment \#1

The manuscript entitled with "Macmoondongtang modulates asthma-related changes via modulation of TNF-a and T-bet & IFN-r in an asthma murine model" brought some interesting findings. However, it is not convincible for its description and conclusion with several reasons as follows:

1\) Macmoondongtang has been used as a traditional prescription for pulmonary disease in Korea. However, there is no report about the mechanism involved in its effect. In the present study, the authors described how Macmoondongtang as a repiratory medicine has effect on Ashma in a murine model. Since Macmoondongtang is a traditional prescription for pulmonary disease, surprisingly, there is no any information on how Macmoondongtang has been clinically used in Ashma treatment at all. So, it is really weird for me to choose Ashma instead of the other disease models for study on Macmoondongtang.

ans) Thank you for your kind advise.

Macmoondongtang has been used as oriental medicine in Korea and China and is still commercialized. Macmoondongtang was generally used to cure bronchitis, asthma, pneumonia, cough, and sputum production. The mechanism of anti-asthmatic activity of Macmoondongtang has not been reported. Therefore, we have demonstrated the anti-asthmatic effect of Macmoondongtangin animal experiments used commercial products (see Materials and methods). The effective dose of Macmoondongtang in animal studies was determined to be 1500 mg/kg. We calculated the dose of human based on the results of animal experiments. Human dose was included in the daily intake range of commercial products (see, discussion section). The important facts in this manuscript are that anti-asthmatic effect has been demonstrated within the stable dose range of Macmoondongtang, and the action mechanism has also been clearly identified.

2\) According to the results, it looks like that Macmoondongtang play role in modulation of expression of Th1, Th2 and Th17-related cytokines. Why did the manuscript choose a tittle as modulation of TNF-a and T-bet & IFN-r? It doesn\'t make any sense to me.

Ans) Thank you so much for your comments and I agreed with your comments. I think that the manuscript title should be changed to "Macmoondongtang controls the asthmatic changes via modulation of Th1-/Th2-/Th17-related factors in an asthma murine model".

3\) The results showed that Macmoondongtang contained glycyrrhizin and liquiritin. Theoretically glycyrrhizin and liquiritin could have some role in modulation of the cytokine expression. But how did you exclude effects of some unknown components in Macmoondongtang.

ans) Thank you for your kind advise. The effective dose of glycyrrhizin was reported to be 2.5-20 mg/kg in the mouse model (Ram et al) and liquiritin has been reported to be efficacious at a minimum dose of 5 mg/kg in mouse model (Ram et al). We reported that in the discussion section that Macmoondongtang contained 0.38% glycyrrhizin. Glycyrrhizin in Macmoondongtang was calculated based on the content and correlated with animal experimental results. The dose of 1500 mg/kg Macmoondongtang is equivalent to 5.7 mg/kg glycyrrhizin. These results are correlated with previous reports (efficacy range 2.5 - 20 mg/kg). It can be interpreted that glycyrrhizin present in Macmoondongtang shows the main anti-asthmatic effect. Based on the content of liquiritin, the effective dose (5 mg/kg or more) is insufficient. Therefore, liquiritin was thought to be a cofactor for anti-asthmatic effect.

Comment \#2

Has the statistical analysis been performed appropriately and rigorously? No Although the manuscript showed thirty-fine mice were divided into five groups, it was not clear of how many mice had being used in each figure. So, it is very confused about how they calculated the data without showing "n" in each figure.

Ans) Thank you so much for your advices. This study was conducted twice time using with 70 heads, for one study 35 mice had been used and using with same method the other study was done. I added this method in the Materials and Methods section and used numbers of animals for each graph was described in the Figure Legends.

Comment \#3

Is the manuscript presented in an intelligible fashion and written in standard English? No

There are a lot of places to be rewrote in a standard English in this manuscript, for example, "It is important to decrease IgE expression increased by ovalbumin treatment", "T-bet is a factor for Th1 cell transcription...., to the end of this paraph", and so on.

Ans) Thank you so much for your advice. Although this manuscript had been edited by professional editing company (I attached the certificate file of editing) revised manuscript would be done by editing company again.

Some minor comments:

1)For material and methods, there were a lot of description to be improved, for example, which samples were used for RNA extraction? how the samples were prepared for IFA? and so on.

Ans) Thank you so much for your comments and I add the description about materials and methods in the Section.

2\) What's magnitude for those microscopic figures? And the quality of those microscopic figures should be also improved.

Ans) Thank you so much for your advice and I added the magnification in each photo. For improving the photos' quality, I adjusted them again.

Reviewer \#2

In this study, Lee et al. reported that macmoondongtang, a traditional prescription for treating respiratory disease, could modulate host immune responses during OVA-induced asthma in a mice model. They reported that macmoondongtang treatment could reduce serum IgE level, mucus hypersecretion, inflammatory cell infiltration in the lungs. They also reported that macmoondongtang treatment leads to reduced expression of Th1/Th2 transcriptional factors as well as related cytokines such as IFN-g, IL-12, IL-4 and IL-5, IL-13 on mRNA level or protein level. The data is interesting; however, the manuscript has severe limitations that the authors need to deal with before publications.

1\. The written Englished should be revised significantly. There are many grammar mistakes in the manuscript.

Ans) Thank you so much for your advice. Although this manuscript had been edited by professional editing company (I attached the certificate file of editing) revised manuscript would be done by editing company again.

2\. The conclusions are overstated and need revision. For example,

a\. it is not convincing that glycyrrhizin and liquiritin were the effective ingredients of macmoondongtang.

ans) Thanks for your kind advise. Macmoondongtang has been used as oriental medicine in Korea and China and is still commercialized. Macmoondongtang was generally used to cure bronchitis, asthma, pneumonia, cough, and sputum production. The mechanism of anti-asthmatic activity of Macmoondongtang has not been reported. Therefore, we have demonstrated the anti-asthmatic effect of Macmoondongtangin animal experiments used commercial products (see Materials and methods). The effective dose of Macmoondongtang in animal studies was determined to be 1500 mg/kg. We calculated the dose of human based on the results of animal experiments. Human dose was included in the daily intake range of commercial products (see, discussion section). The important facts in this manuscript are that anti-asthmatic effect has been demonstrated within the stable dose range of Macmoondongtang, and the action mechanism has also been clearly identified.

liquiritin and glycyrrhizin were designated as the main marker of Macmoondongtang and the test method for content analysis

(see. <https://oasis.kiom.re.kr/oasis/pres/prdetailView2.jsp?idx=32&selectname=null&srch_menu_nix=null#view04>) was defined in KFDA (Korea Food & Drug Administration). In this study, we confirmed that liquiritin and glycyrrhizin are markers for quality control and one of the effective markers.

b\. There is no data supporting the title: "Macmoondongtang modulates asthma-related changes via modulation of TNF-a andTbet& IFN-g in an asthma murine model". They showed correlation, nut not causality.

Ans) Thank you so much for your comments and I agreed with your comments. I think that the manuscript title should be changed to "Macmoondongtang controls the asthmatic changes via modulation of Th1-/Th2-/Th17-related factors in an asthma murine model"

3\. The reviewer also concerned about the quality of some data. For example, fig 5, it is hard to tell the localization of the transcriptional factors (Tbet and GATA3) at the current magnification. Fig 6, 7, 8, it would be nice to quantify the IHC signals.

Ans) Thank you so much for your comments. We focused the localization of specific protein in the lung tissue such as in nucleus or in cytoplasm and I evaluated the localization of them based on the criteria that in dissimilar to general color when the different colors of light exist are summed-up they change the white color. Therefore, in the asthma-induction group we could evaluated that both of T-bet (green color) and GATA-3 (red color) existed in the nucleus (blue color) as in the nucleus the white spots were found compared to the other groups.

4\. Methods are missing: RNA isolation, cDNA synthesis, qPCR methods, Elisa for IgE,

Ans) Thank you so much for your comments and I add the description about materials and methods in the Section.

5\. Fig 1, please also include the control HPLC data for glycyrrhizin and liquiritin

Ans) Thank you for your kind advise. we modified the figure 1 according to reviewers' recommendation.

6\. For statistical analysis, how many times have these experiments been repeated? It says mean ± SEM in the figure legends but mean ± SD in the Materias and Methods, which one is correct?

Ans) Thank you so much for your comment and there were typos. I amended the expression as "mean ± SD".

###### 
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###### 
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PONE-D-19-17023R1

Macmoondongtang alleviates asthma via modulation of Th1-/Th2-/Th17-related cytokines in a murine model of asthma

PLOS ONE

Dear Professor Park,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

While the manuscript has improved, both reviewers remain concerned about the over-interpretation of findings/speculative conclusions not fully supported by the data. In order to comply with PLOS publication policy the conclusions need to fully support by the data presented. Although, your data identified a link between the therapeutic effects of Macmoondongtang and certain group of cytokine responses, but they are insufficient to proof that it is the mechanism of drug action. Thus, the conclusions and title of the manuscript need to be adjusted as suggested by the Reviewer 2.

We would appreciate receiving your revised manuscript by Oct 21 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Michal A Olszewski, DVM, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Major comments:

After revise, the manuscript has been improved by the authors. But two major things still remain to be improved, as follows:

1, the writing must be improved. 1) introduction, special paragraph 2 and 3, is not so clear to this study; 2) discussion, which has been improved is not enough. Furthermore, some description is misleading, such as the synergistic role between glycyrrhizin and liquiritin unless there are some experimental finding available.

2, the microscropic figures are in a low quality. My previous comment has mentioned this problem. The authors\' response was that it had been adjusted. But there are not clear, I don\'t know why.

Minor comments:

1, there are still some grammar mistakes to be checked.

2, ref \#8, is not completed.

Reviewer \#2: In this revised manuscript, the authors report that macmoondongtang could regulate host immune response in a murine model of asthma. Specifically, mice treated with macmoondongtang show decreased neutrophil count in BALF, reduced T-bet, IFN-g, and TNF-a, IL-12, IL-4, and IL-5 genes expression in the lung. While most of my previous concerns have been addressed, the reviewer still has some minor comments about several conclusions in the manuscript. The authors provide no data supports that modulation of Th1/Th2 cytokines is the mechanism of how Macmoondongtang alleviates asthma.

1\. I would suggest change the title to "Macmoondongtang modulates Th1-/Th2-related cytokines and alleviates asthma in a murine model".

2\. I would suggest modify the conclusions to: "Macmoondongtang treatment alleviates asthma symptoms and modulate the Th1-/Th2- related cytokines. Glycyrrhizin and liquiritin could be the major the active therapeutic components".

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

17 Sep 2019

Reviewer \#1: Major comments:

After revise, the manuscript has been improved by the authors. But two major things still remain to be improved, as follows:

1, the writing must be improved. 1) introduction, special paragraph 2 and 3, is not so clear to this study; 2) discussion, which has been improved is not enough. Furthermore, some description is misleading, such as the synergistic role between glycyrrhizin and liquiritin unless there are some experimental finding available.

Ans) Thank you so much for your comments and I amended several parts depended on your comments. As I agreed with your suggestions and omitted the sentence about the synergistic effects of glycyrrhizin and liquiritin.

2, the microscropic figures are in a low quality. My previous comment has mentioned this problem. The authors\' response was that it had been adjusted. But there are not clear, I don\'t know why.

Ans) Thank you so much for your comments and all of figures were prepared as tiff files. Although all of them are made which met on the publication criteria during uploading the manuscript they might be unclearly changed. Please understand my situation.

Minor comments:

1, there are still some grammar mistakes to be checked.

Ans) The manuscript was edited by editing company and I attached the certificate of edit.

2, ref \#8, is not completed.

Ans) Thank you so much for your comment and I amended the reference \#8.

Reviewer \#2: In this revised manuscript, the authors report that macmoondongtang could regulate host immune response in a murine model of asthma. Specifically, mice treated with macmoondongtang show decreased neutrophil count in BALF, reduced T-bet, IFN-g, and TNF-a, IL-12, IL-4, and IL-5 genes expression in the lung. While most of my previous concerns have been addressed, the reviewer still has some minor comments about several conclusions in the manuscript. The authors provide no data supports that modulation of Th1/Th2 cytokines is the mechanism of how Macmoondongtang alleviates asthma.

1\. I would suggest change the title to "Macmoondongtang modulates Th1-/Th2-related cytokines and alleviates asthma in a murine model".

Ans) Thank you so much for your suggestion and I amended the manuscript's title.

2\. I would suggest modify the conclusions to: "Macmoondongtang treatment alleviates asthma symptoms and modulate the Th1-/Th2- related cytokines. Glycyrrhizin and liquiritin could be the major the active therapeutic components".

Ans) Thank you so much for your suggestion and I amended the manuscript's title.
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Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

8 Oct 2019

PONE-D-19-17023R2

Macmoondongtang modulates Th1-/Th2-related cytokines and alleviates asthma in a murine model

PLOS ONE

Dear Professor Park,

Thank you for submitting your manuscript to PLOS ONE. The manuscript has greatly improved and virtually all the issues have been resolved with one exception of \"overlooked\" conclusion adjustment as noted by the Reviewer 2. Therefore, we invite you to complete the final round of revisions and submit the revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Nov 22 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Michal A Olszewski, DVM, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: My comment 2 is not addressed in the revised manuscript. Please change the conlusions on page 3.

I would suggest to modify the conclusions to: "Macmoondongtang treatment alleviates asthma symptoms and modulate the Th1-/Th2- related cytokines. Glycyrrhizin and liquiritin could be the major the active therapeutic components".

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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10 Oct 2019

Reviewer \#2:

1\. My comment 2 is not addressed in the revised manuscript. Please change the conlusions on page 3. I would suggest to modify the conclusions to: "Macmoondongtang treatment alleviates asthma symptoms and modulate the Th1-/Th2- related cytokines. Glycyrrhizin and liquiritin could be the major the active therapeutic components".

Ans) Thank you so much for your suggestion and I amended the conclusion part in the abstract.
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Dear Dr. Park,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Michal A Olszewski, DVM, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:
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Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

14 Nov 2019

PONE-D-19-17023R3

Macmoondongtang modulates Th1-/Th2-related cytokines and alleviates asthma in a murine model

Dear Dr. Park:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Michal A Olszewski

Academic Editor

PLOS ONE
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